FAQ: Lantern Pharma CEO Featured on BioMedWire Podcast Discussing AI-Driven Oncology Progress
Summary
Lantern Pharma CEO Panna Sharma was featured on IBN's BioMedWire Podcast discussing the company's AI-driven approach to accelerating cancer drug development and progress in three ongoing clinical trials.
What is the main topic of the BioMedWire Podcast featuring Lantern Pharma?
The podcast features Lantern Pharma CEO Panna Sharma discussing the company’s mission to accelerate cancer drug development using AI, outlining progress across three ongoing clinical trials, and sharing his outlook on the future of precision neuro-oncology.
What is Lantern Pharma’s proprietary AI platform called?
Lantern Pharma’s proprietary AI platform is called RADR®, which uses machine learning and multiomic data to solve complex drug development challenges in oncology.
How does Lantern Pharma’s AI platform transform cancer drug development?
The RADR® AI platform transforms oncology drug discovery and development by reducing costs, shortening development time, and lowering failure rates through machine learning and multiomic data analysis.
What is the significance of Lantern Pharma’s clinical progress mentioned in the podcast?
The company has three ongoing clinical trials and has built a pipeline of promising clinical stage drug candidates, including molecules targeting novel cancer mechanisms and targets, demonstrating tangible progress in AI-driven oncology.
Where can investors find the latest news and updates about Lantern Pharma (LTRN)?
The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
What is BioMedWire and what services does it provide?
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, offering wire solutions, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
How can readers access the full press release about this podcast feature?
The full press release can be viewed at https://ibn.fm/ITg2o.
What makes BioMedWire uniquely positioned to serve companies in the biotech sector?
BioMedWire has broad reach with a seasoned team of journalists and writers, cutting through information overload to provide clients with unparalleled recognition and brand awareness through its specialized focus and comprehensive distribution network.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 204369